×
About 610 results

ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center

Research & Reviews  222 results

Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma.
https://doi.org/10.1002/cam4.4200
Cancer Medicine; Arakawa F, Miyoshi H et. al.

Sep 4th, 2021 - Telomere length is maintained by the activation of telomerase, which causes continuous cell division and proliferation in many carcinomas. A catalytic reverse transcriptase protein (TERT) encoded by the TERT gene plays a critical role in the activ...

Angioimmunoblastic T-cell lymphoma diagnosed from pleural fluid by integration of morph...
https://doi.org/10.1002/dc.24861
Diagnostic Cytopathology; Tan B, Martin B et. al.

Aug 28th, 2021 - An 88-year-old man with end-stage renal disease on hemodialysis presented with shortness of breath and was found to have lower extremity edema and bilateral pleural effusions on a chest X-ray. A therapeutic and diagnostic thoracentesis was perform...

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report fro...
https://doi.org/10.1182/blood.2020010387
Blood Advani RH, Skrypets T et. al.

Jul 23rd, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 and 2018...

Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment.
https://doi.org/10.1097/CCO.0000000000000773 10.1182/blood.2020010387.
Current Opinion in Oncology; Tari G, Lemonnier F et. al.

Jul 8th, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is a frequent peripheral T-cell lymphoma affecting elderly patients with a poor outcome when treated with conventional chemotherapy. Molecular studies revealed a homogenous mutational landscape gathering a...

see more →

Clinicaltrials.gov  2 results

Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01336920

Jul 27th, 2018 - PRIMARY OBJECTIVES: I. To establish the maximum tolerated dose (MTD) of single agent carfilzomib in patients with relapsed and refractory peripheral T-cell lymphoma (PTCL) including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell ...

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01336933

Jun 25th, 2018 - PRIMARY OBJECTIVES: I. To evaluate in a Phase II study a preliminary estimate of the complete response (CR) rate of a new chemotherapy regimen involving Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) alternating with Pralatrexate (...

see more →

News  20 results

T-cell lymphoma registries: What have we learned?
https://www.mdedge.com/hematology-oncology/article/207981/t-cell-lymphomas/t-cell-lymphoma-registries-what-have-we-learned?channel=39313
Jennifer Smith

Sep 11th, 2019 - Registries for T-cell lymphoma have improved our understanding of the disease, but many questions remain. Could combining the various registries provide more answers? “[T]here are many, many different registries around the world,” said Owen O’Conn.

Angioimmunoblastic T-cell Lymphoma: Patient Characteristics and Survival Outcomes
https://www.mdedge.com/fedprac/avaho/article/207820/lymphoma-plasma-cell-disorders/angioimmunoblastic-t-cell-lymphoma?channel=53
Ermann DA, Vardell VA et. al.

Sep 9th, 2019 - Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive malignancy, representing approximately 18. 5% of Peripheral T-cell lymphomas.

HDAC/HMA combo shows ‘remarkable’ activity in PTCL
https://www.mdedge.com/hematology-oncology/article/206189/t-cell-lymphomas/hdac/hma-combo-shows-remarkable-activity-ptcl?channel=303
Neil Osterweil

Aug 9th, 2019 - LUGANO, SWITZERLAND – A combination of 5-azacytidine and romidepsin showed promising activity in patients with peripheral T cell lymphomas, particularly angioimmunoblastic T-cell lymphoma (AITL) and primary cutaneous follicular helper T-cell lymph.

Cerdulatinib yields ‘encouraging’ results in CTCL, PTCL
https://www.mdedge.com/hematology-oncology/article/193975/lymphoma-plasma-cell-disorders/cerdulatinib-yields-encouraging?channel=39313
Jennifer Smith

Feb 6th, 2019 - LA JOLLA, CALIF. – The spleen tyrosine kinase/Janus kinase inhibitor cerdulatinib has demonstrated activity against relapsed and refractory T-cell lymphomas.

Combo emerges as bridge to transplant in rel/ref PTCL
https://www.mdedge.com/hematology-oncology/article/193912/lymphoma-plasma-cell-disorders/combo-emerges-bridge-transplant/page/0/1?channel=39313

Feb 5th, 2019 - Efficacy with romidepsin Among all evaluable PTCL patients in the romidepsin arm, the ORR was 59% (16/27), and the CR rate was 33% (9/27). Responses occurred in seven patients with PTCL not otherwise specified (NOS), six with angioimmunoblastic T-.

see more →